Implementing prognostic and predictive biomarkers in CRC clinical trials

Nature Reviews Clinical Oncology

Volumn 8, Issue 4, 2011, Pages 222-232

  Van Schaeybroeck, Sandra ^a   Allen, Wendy L ^a   Turkington, Richard C ^a   Johnston, Patrick G ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; ANTINEOPLASTIC AGENT; B RAF KINASE; BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CETUXIMAB; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIREGULIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIK3CA PROTEIN; SORAFENIB; TRASTUZUMAB; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG;

ACCURACY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CANCER RESEARCH; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENICITY; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; CONTINUOUS INFUSION; DRUG EFFECT; DRUG RESPONSE; DRUG SENSITIVITY; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE MUTATION; HUMAN; MARKER GENE; METASTASIS; MICROARRAY ANALYSIS; MICROSATELLITE INSTABILITY; MOLECULAR DYNAMICS; MULTIPLE CYCLE TREATMENT; PREDICTIVE VALUE; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; TREATMENT DURATION; VALIDATION PROCESS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; PROGNOSIS; RESEARCH DESIGN; TUMOR MARKERS, BIOLOGICAL;

EID: 79953243501     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2011.15     Document Type: Review

References (126)

1. Benson, A. B. 3rd et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J. Clin. Oncol. 22, 3408-3419 (2004).
2. Boland, C. R. et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 58, 5248-5257 (1998). (Pubitemid 28521189)
3. Tejpar, S. et al. Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial) [abstract]. J. Clin. Oncol. 27 (15 Suppl.), a4001 (2009).
4. Koopman, M. et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br. J. Cancer 100, 266-273 (2009).
5. Watanabe, T. et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 344, 1196-1206 (2001). (Pubitemid 32319494)
6. Ribic, C. M. et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 349, 247-257 (2003). (Pubitemid 36859476)
7. French, A. J. et al. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin. Cancer Res. 14, 3408-3415 (2008).
8. Popat, S., Hubner, R. & Houlston, R. S. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol. 23, 609-618 (2005). (Pubitemid 46224239)
9. Hutchins, G. et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a3517 (2010).
10. Sinicrope, F. et al. DNA mismatch repair status and site of tumor recurrence in stage II and III colon cancers treated in 5-fluorouracil-based adjuvant therapy trials [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a3519 (2010).
11. Kim, G. P. et al. Analysis of time-dependent patterns of treatment effect and failure to explain the predictive role of deficient mismatch repair (dMMR) in stage II and III colon cancer (CC) [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a3518 (2010).
12. Roth, A. D. et al. Stage-specific prognostic value of molecular markers in colon cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial [abstract]. J. Clin. Oncol. 27 (15 Suppl.), a4002 (2009).
13. Elsaleh, H. et al. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355, 1745-1750 (2000). (Pubitemid 30265078)
14. Sargent, D. J. et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J. Clin. Oncol. 28, 3219-3226 (2010).
15. Bertagnolli, M. M. et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J. Clin. Oncol. 27, 1814-1821 (2009).
16. Hawkins, N. et al. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 122, 1376-1387 (2002). (Pubitemid 34465180)
17. Kambara, T. et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 53, 1137-1144 (2004). (Pubitemid 38961968)
18. Ogino, S. et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58, 90-96 (2009).
19. Dahlin, A. M. et al. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clin. Cancer Res. 16, 1845-1855 (2010).
20. Van Rijnsoever, M., Elsaleh, H., Joseph, D., McCaul, K. & Iacopetta, B. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin. Cancer Res. 9, 2898-2903 (2003). (Pubitemid 36993247)
21. Andreyev, H. J., Norman, A. R., Cunningham, D., Oates, J. R. & Clarke, P. A. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J. Natl Cancer Inst. 90, 675-684 (1998). (Pubitemid 28222141)
22. Andreyev, H. J. et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br. J. Cancer 85, 692-696 (2001). (Pubitemid 32929467)
23. Richman, S. D. et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J. Clin. Oncol. 27, 5931-5937 (2009).
24. Barault, L. et al. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res. 68, 8541-8546 (2008).
25. Wang, C. et al. Prognostic significance of microsatellite instability and Ki-ras mutation type in stage II colorectal cancer. Oncology 64, 259-265 (2003). (Pubitemid 36438811)
26. Roth, A. D. et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J. Clin. Oncol. 28, 466-474 (2010).
27. Ogino, S. et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin. Cancer Res. 15, 7322-7329 (2009).
28. Lièvre, A. et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66, 3992-3995 (2006).
29. Lièvre, A. et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26, 374-379 (2008). (Pubitemid 351171687)
30. Moroni, M. et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 6, 279-286 (2005). (Pubitemid 40590264)
31. Freeman, D. J. et al. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin. Colorectal Cancer 7, 184-190 (2008). (Pubitemid 351758148)
32. De Roock, W. et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann. Oncol. 19, 508-515 (2008). (Pubitemid 351325672)
33. Khambata-Ford, S. et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 25, 3230-3237 (2007). (Pubitemid 47325606)
34. Benvenuti, S. et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 67, 2643-2648 (2007). (Pubitemid 46548951)
35. Frattini, M. et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br. J. Cancer 97, 1139-1145 (2007). (Pubitemid 47587019)
36. Di Fiore, F. et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br. J. Cancer 96, 1166-1169 (2007). (Pubitemid 46625066)
37. Finocchiaro, G. et al. EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer [abstract]. J. Clin. Oncol. 25 (18 Suppl.), a4021 (2007).
38. Di Fiore, F. et al. Role of KRAS mutation in predicting response, progression-free survival, and overall survival in irinotecan-refractory patients treated with cetuximab plus irinotecan for a metastatic colorectal cancer: Analysis of 281 individual data from published series [abstract]. J. Clin. Oncol. 26 (May 20 Suppl.), a4035 (2008).
39. Amado, R. G. et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 1626-1634 (2008).
40. Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757-1765 (2008).
41. Bokemeyer, C. et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27, 663-671 (2009).
42. Van Cutsem, E. et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408-1417 (2009).
43. Van Cutsem, E. et al. Cetuximab plus FOLFIRI: Final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a3570 (2010).
44. Siena, S. et al. Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared to FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial [abstract]. ASCO Gastrointestinal Cancers Symposium 283 (2010).
45. Peeters, M. et al. Randomized phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Patient-reported outcomes (PRO) [abstract]. ASCO Gastrointestinal Cancers Symposium 282 (2010).
46. Hurwitz, H. I., Yi, J., Ince, W., Novotny, W. F. & Rosen, O. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 14, 22-28 (2009).
47. Allegra, C. J. et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 27, 2091-2096 (2009).
48. Takezawa, K. et al. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells. Cancer Res. 69, 6515-6521 (2009).
49. Haigis, K. M. et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat. Genet. 40, 600-608 (2008). (Pubitemid 351601205)
50. Scholl, C. et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137, 821-834 (2009).
51. Loupakis, F. et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br. J. Cancer 101, 715-721 (2009).
52. Di Nicolantonio, F. et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 26, 5705-5712 (2008).
53. Li, W. Q. et al. BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol. Cancer 5, 2 (2006).
54. Vilkin, A. et al. Microsatellite instability, MLH1 promoter methylation, and BRAF mutation analysis in sporadic colorectal cancers of different ethnic groups in Israel. Cancer 115, 760-769 (2009).
55. Kumar, K. et al. Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal cancer in African Americans. Clin. Cancer Res. 15, 1155-1161 (2009).
56. Souglakos, J. et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br. J. Cancer 101, 465-472 (2009).
57. Bokemeyer, C. et al. Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a3506 (2010).
58. Tran, B. et al. Differences in sites of metastatic disease and outcomes observed in patients with BRAF mutant colorectal cancers [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a3592 (2010).
59. Tejpar, S. et al. Mutant KRAS and BRAF gene expression profiles in colorectal cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a3505 (2010).
60. Laurent-Puig, P. et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J. Clin. Oncol. 27, 5924-5930 (2009).
61. Bokemeyer, C. et al. Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a3506 (2010).
62. Jhawer, M. et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res. 68, 1953-1961 (2008). (Pubitemid 351416582)
63. Perrone, F. et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann. Oncol. 20, 84-90 (2009).
64. Sartore-Bianchi, A. et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 69, 1851-1857 (2009).
65. Prenen, H. et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin. Cancer Res. 15, 3184-3188 (2009).
66. Loupakis, F. et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J. Clin. Oncol. 27, 2622-2629 (2009).
67. De Roock, W. et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 11, 753-762 (2010).
68. Zhao, L. & Vogt, P. K. Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle 9, 596-600 (2010).
69. Jacobs, B. et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J. Clin. Oncol. 27, 5068-5074 (2009).
70. Kyula, J. N. et al. Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer. Clin. Cancer Res. 16, 3378-3389 (2010).
71. Maxwell, P. J. et al. Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling. Cancer Res. 63, 4602-4606 (2003). (Pubitemid 36951036)
72. Boyer, J. et al. Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res. 66, 2765-2777 (2006).
73. Al-Mulla, F., Keith, W. N., Pickford, I. R., Going, J. J. & Birnie, G. D. Comparative genomic hybridization analysis of primary colorectal carcinomas and their synchronous metastases. Genes Chromosomes Cancer 24, 306-314 (1999). (Pubitemid 29115868)
74. Gaasenbeek, M. et al. Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex changes and multiple forms of chromosomal instability in colorectal cancers. Cancer Res. 66, 3471-3479 (2006).
75. Lips, E. H. et al. Reliable high-throughput genotyping and loss-of-heterozygosity detection in formalin-fixed, paraffin-embedded tumors using single nucleotide polymorphism arrays. Cancer Res. 65, 10188-10191 (2005). (Pubitemid 41743709)
76. Chan, E. C. et al. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J. Proteome Res. 8, 352-361 (2009).
77. Denkert, C. et al. Metabolite profiling of human colon carcinoma-deregulation of TCA cycle and amino acid turnover. Mol. Cancer 7, 72 (2008).
78. Luo, J. et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137, 835-848 (2009).
79. Thomas, R. K. et al. High-throughput oncogene mutation profiling in human cancer. Nat. Genet. 39, 347-351 (2007). (Pubitemid 46328493)
80. Bild, A. H. et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439, 353-357 (2006). (Pubitemid 43128862)
81. Mariadason, J. M. et al. Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res. 63, 8791-8812 (2003). (Pubitemid 38064059)
82. Arango, D. et al. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br. J. Cancer 91, 1931-1946 (2004). (Pubitemid 40065523)
83. Allen, W. L. et al. Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin. Cancer Res. 14, 6647-6655 (2008).
84. Nagrath, S. et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450, 1235-1239 (2007).
85. Cohen, S. J. et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann. Oncol. 20, 1223-1229 (2009).
86. Sastre, J. et al. Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann. Oncol. 19, 935-938 (2008). (Pubitemid 351627310)
87. Holdhoff, M., Schmidt, K., Donehower, R. & Diaz, L. A. Jr. Analysis of circulating tumor DNA to confirm somatic KRAS mutations. J. Natl Cancer Inst. 101, 1284-1285 (2009).
88. van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002). (Pubitemid 35461656)
89. van 't Veer, L. J. & Weigelt, B. Road map to metastasis. Nat. Med. 9, 999-1000 (2003). (Pubitemid 37021777)
90. Weigelt, B. et al. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc. Natl Acad. Sci. USA 100, 15901-15905 (2003). (Pubitemid 38021087)
91. Glas, A. M. et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 7, 278 (2006).
92. Buyse, M. et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl Cancer Inst. 98, 1183-1192 (2006). (Pubitemid 44390989)
93. van 't Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
94. Wang, Y. et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J. Clin. Oncol. 22, 1564-1571 (2004). (Pubitemid 41079793)
95. Barrier, A. et al. Colon cancer prognosis prediction by gene expression profiling. Oncogene 24, 6155-6164 (2005). (Pubitemid 43080065)
96. Barrier, A. et al. Stage II colon cancer prognosis prediction by tumor gene expression profiling. J. Clin. Oncol. 24, 4685-4691 (2006). (Pubitemid 46630932)
97. Eschrich, S. et al. Molecular staging for survival prediction of colorectal cancer patients. J. Clin. Oncol. 23, 3526-3535 (2005).
98. O'Connell, M. J. et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J. Clin. Oncol. 28, 3937-3944 (2010).
99. Kerr, D. et al. A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. J. Clin. Oncol. 27 (15 Suppl.), abstr 4000 (2009).
100. O'Connell, M. J. et al. Comparison of molecular and pathologic features of stage II and stage III colon cancer in four large studies conducted for development of the 12-gene colon cancer recurrence score [abstract]. ASCO Gastrointestinal Cancers Symposium 280 (2010).
101. Rosenberg, R. et al. Independent validation of a prognostic genomic profile (ColoPrint) for stage II colon cancer (CC) patients [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a3513 (2010).
102. Pogue-Geile, K. L. et al. Use of a prognostic (prog) gene index and nodal status to identify a subset of stage II and III colon cancer patients (pts) who may not need oxaliplatin (ox)-containing adjuvant chemotherapy [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a3516 (2010).
103. Del Rio, M. et al. Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J. Clin. Oncol. 25, 773-780 (2007). (Pubitemid 350002876)
104. de Reyniès, A., Boige, V., Milano, G., Faivre, J. & Laurent-Puig, P. KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature. J. Clin. Oncol. 26, 2228-2230 (2008).
105. Wang, Y., Miller, D. J. & Clarke, R. Approaches to working in high-dimensional data spaces: gene expression microarrays. Br. J. Cancer 98, 1023-1028 (2008). (Pubitemid 351399797)
106. Simon, R. Roadmap for developing and validating therapeutically relevant genomic classifiers. J. Clin. Oncol. 23, 7332-7341 (2005). (Pubitemid 46202346)
107. Simon, R., Radmacher, M. D., Dobbin, K. & McShane, L. M. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J. Natl Cancer Inst. 95, 14-18 (2003). (Pubitemid 36124291)
108. Shi, L. et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat. Biotechnol. 24, 1151-1161 (2006). (Pubitemid 44359727)
109. Ramaswamy, S. & Golub, T. R. DNA microarrays in clinical oncology. J. Clin. Oncol. 20, 1932-1941 (2002). (Pubitemid 34273286)
110. Chen, J., Byrne, G. E. Jr & Lossos, I. S. Optimization of RNA extraction from formalin-fixed, paraffin-embedded lymphoid tissues. Diagn. Mol. Pathol. 16, 61-72 (2007). (Pubitemid 47164737)
111. Bibikova, M. et al. Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays. Am. J. Pathol. 165, 1799-1807 (2004). (Pubitemid 39435177)
112. Horlings, H. M. et al. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J. Clin. Oncol. 26, 4435-4441 (2008).
113. Farragher, S. M., Tanney, A., Kennedy, R. D. & Paul Harkin, D. RNA expression analysis from formalin fixed paraffin embedded tissues. Histochem. Cell Biol. 130, 435-445 (2008).
114. Pepe, M. S. et al. Phases of biomarker development for early detection of cancer. J. Natl Cancer Inst. 93, 1054-1061 (2001). (Pubitemid 32717537)
115. Mandrekar, S. J. & Sargent, D. J. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J. Clin. Oncol. 27, 4027-4034 (2009).
116. Simon, R. The use of genomics in clinical trial design. Clin. Cancer Res. 14, 5984-5993 (2008).
117. Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001). (Pubitemid 32222155)
118. Maitournam, A. & Simon, R. On the efficiency of targeted clinical trials. Stat. Med. 24, 329-339 (2005). (Pubitemid 40227650)
119. Simon, R. & Maitournam, A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin. Cancer Res. 10, 6759-6763 (2004). (Pubitemid 39383023)
120. Simon, R. Clinical trials for predictive medicine: new challenges and paradigms. Clin. Trials 7, 516-524 (2010).
121. Simon, R. & Wang, S. J. Use of genomic signatures in therapeutics development in oncology and other diseases. Pharmacogenomics J. 6, 166-173 (2006). (Pubitemid 43811567)
122. Mandrekar, S. J., Grothey, A., Goetz, M. P. & Sargent, D. J. Clinical trial designs for prospective validation of biomarkers. Am. J. Pharmacogenomics 5, 317-325 (2005). (Pubitemid 41425609)
123. Sargent, D. J., Conley, B. A., Allegra, C. & Collette, L. Clinical trial designs for predictive marker validation in cancer treatment trials. J. Clin. Oncol. 23, 2020-2027 (2005). (Pubitemid 46211382)
124. Mandrekar, S. J. & Sargent, D. J. Clinical trial designs for predictive biomarker validation: one size does not fit all. J. Biopharm. Stat. 19, 530-542 (2009).
125. Jiang, W., Freidlin, B. & Simon, R. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. J. Natl Cancer Inst. 99, 1036-1043 (2007). (Pubitemid 47232604)
126. Wang, S. J., O'Neill, R. T. & Hung, H. M. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharm. Stat. 6, 227-244 (2007). (Pubitemid 47455262)